Seeking Alpha

Sagent Pharmaceuticals (SGNT) announces the approval and launch of its Zoledronic Acid...

Sagent Pharmaceuticals (SGNT) announces the approval and launch of its Zoledronic Acid Injection, the generic form of Zometa, in a plastic vial. The U.S. market for Zoledronic Acid Injection is approximately $606M. Additionally, the company says its amended its manufacturing and supply agreement with Actavis (ACT) which provides for an enhanced profit split in favor of SGNT, plus a revised line-up of products and a one-time termination fee of $5 million payable to Sagent.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs